The expansion is expected to support growth with revenues and profits estimated to rise by 20-25 per cent over the FY20-23 period
from Latest News https://ift.tt/2PlNNtn
Friday, 2 April 2021
Rossari Biotech IPO: A diversified portfolio, expansion are key triggers
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment